FPH Stock Overview
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide.
FPH passed our risk checks.
Fisher & Paykel Healthcare Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$19.10|
|52 Week High||NZ$34.55|
|52 Week Low||NZ$18.81|
|1 Month Change||-5.45%|
|3 Month Change||-4.98%|
|1 Year Change||-40.54%|
|3 Year Change||10.41%|
|5 Year Change||50.28%|
|Change since IPO||4,144.44%|
Recent News & Updates
Calculating The Fair Value Of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH)
Today we will run through one way of estimating the intrinsic value of Fisher & Paykel Healthcare Corporation Limited...
|FPH||NZ Medical Equipment||NZ Market|
Return vs Industry: FPH underperformed the NZ Medical Equipment industry which returned -29.7% over the past year.
Return vs Market: FPH underperformed the NZ Market which returned -17% over the past year.
|FPH Average Weekly Movement||4.5%|
|Medical Equipment Industry Average Movement||11.4%|
|Market Average Movement||3.8%|
|10% most volatile stocks in NZ Market||8.0%|
|10% least volatile stocks in NZ Market||2.7%|
Stable Share Price: FPH is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: FPH's weekly volatility (4%) has been stable over the past year.
About the Company
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system.
Fisher & Paykel Healthcare Fundamentals Summary
|FPH fundamental statistics|
Is FPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FPH income statement (TTM)|
|Cost of Revenue||NZ$629.00m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Nov 29, 2022
|Earnings per share (EPS)||0.65|
|Net Profit Margin||22.41%|
How did FPH perform over the long term?See historical performance and comparison
2.1%Current Dividend Yield
Is FPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FPH?
Other financial metrics that can be useful for relative valuation.
|What is FPH's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does FPH's PE Ratio compare to its peers?
|FPH PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
EBO EBOS Group
RYM Ryman Healthcare
SUM Summerset Group Holdings
FPH Fisher & Paykel Healthcare
Price-To-Earnings vs Peers: FPH is expensive based on its Price-To-Earnings Ratio (29.3x) compared to the peer average (16x).
Price to Earnings Ratio vs Industry
How does FPH's PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: FPH is expensive based on its Price-To-Earnings Ratio (29.3x) compared to the Global Medical Equipment industry average (22.1x)
Price to Earnings Ratio vs Fair Ratio
What is FPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||29.3x|
|Fair PE Ratio||17.7x|
Price-To-Earnings vs Fair Ratio: FPH is expensive based on its Price-To-Earnings Ratio (29.3x) compared to the estimated Fair Price-To-Earnings Ratio (17.7x).
Share Price vs Fair Value
What is the Fair Price of FPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FPH (NZ$19.1) is trading below our estimate of fair value (NZ$20.71)
Significantly Below Fair Value: FPH is trading below fair value, but not by a significant amount.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Fisher & Paykel Healthcare forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FPH's forecast earnings growth (2.8% per year) is above the savings rate (2.1%).
Earnings vs Market: FPH's earnings (2.8% per year) are forecast to grow slower than the NZ market (5.9% per year).
High Growth Earnings: FPH's earnings are forecast to grow, but not significantly.
Revenue vs Market: FPH's revenue (4.3% per year) is forecast to grow slower than the NZ market (5.6% per year).
High Growth Revenue: FPH's revenue (4.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FPH's Return on Equity is forecast to be low in 3 years time (18.5%).
Discover growth companies
How has Fisher & Paykel Healthcare performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FPH has high quality earnings.
Growing Profit Margin: FPH's current net profit margins (22.4%) are lower than last year (26.6%).
Past Earnings Growth Analysis
Earnings Trend: FPH's earnings have grown significantly by 25% per year over the past 5 years.
Accelerating Growth: FPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: FPH had negative earnings growth (-28.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (-28.1%).
Return on Equity
High ROE: FPH's Return on Equity (22.4%) is considered high.
Discover strong past performing companies
How is Fisher & Paykel Healthcare's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: FPH's short term assets (NZ$887.9M) exceed its short term liabilities (NZ$303.9M).
Long Term Liabilities: FPH's short term assets (NZ$887.9M) exceed its long term liabilities (NZ$123.4M).
Debt to Equity History and Analysis
Debt Level: FPH has more cash than its total debt.
Reducing Debt: FPH's debt to equity ratio has reduced from 9.4% to 4.1% over the past 5 years.
Debt Coverage: FPH's debt is well covered by operating cash flow (474.8%).
Interest Coverage: FPH's interest payments on its debt are well covered by EBIT (219.8x coverage).
Discover healthy companies
What is Fisher & Paykel Healthcare current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: FPH's dividend (2.07%) isn’t notable compared to the bottom 25% of dividend payers in the NZ market (2.85%).
High Dividend: FPH's dividend (2.07%) is low compared to the top 25% of dividend payers in the NZ market (6.04%).
Stability and Growth of Payments
Stable Dividend: FPH's dividend payments have been volatile in the past 10 years.
Growing Dividend: FPH's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (60.5%), FPH's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (147.7%), FPH's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lewis Gradon (61 yo)
Mr. Lewis G. Gradon has been the Chief Executive Officer, Managing Director & Executive Director at Fisher & Paykel Healthcare Corporation Limited since April 1, 2016. He served as the Senior Vice Presiden...
CEO Compensation Analysis
Compensation vs Market: Lewis's total compensation ($USD2.31M) is about average for companies of similar size in the NZ market ($USD1.80M).
Compensation vs Earnings: Lewis's compensation has been consistent with company performance over the past year.
Experienced Management: FPH's management team is considered experienced (5 years average tenure).
Experienced Board: FPH's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: FPH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|09 Sep 22||BuyNZ$25,000||Cather Simpson||Individual||1,250||NZ$20.00|
|29 Aug 22||BuyNZ$108,288||Lisa E. McIntyre||Individual||5,500||NZ$19.69|
|26 Aug 22||BuyNZ$10,150||Scott St John||Individual||500||NZ$20.30|
|01 Jun 22||BuyNZ$11,574||Scott St John||Individual||500||NZ$23.15|
|26 May 22||BuyNZ$31,163,268||Eaton Vance Management||Company||1,184,516||NZ$32.61|
|26 May 22||BuyNZ$317,798,277||First Sentier Investors (Australia) IM Ltd||Company||12,105,875||NZ$32.80|
|26 May 22||BuyNZ$258,845,308||Morgan Stanley, Investment Banking and Brokerage Investments||Company||9,431,145||NZ$33.96|
|26 May 22||SellNZ$12,351,382||Eaton Vance Management||Company||448,439||NZ$32.58|
|26 May 22||SellNZ$188,209,167||First Sentier Investors (Australia) IM Ltd||Company||6,697,338||NZ$28.94|
|26 May 22||SellNZ$303,310,826||Morgan Stanley, Investment Banking and Brokerage Investments||Company||10,825,275||NZ$33.94|
|25 May 22||BuyNZ$1,983,959||Mitsubishi UFJ Trust and Banking Corporation, Asset Management Arm||Company||79,480||NZ$24.96|
|24 May 22||SellNZ$166,196||Morgan Stanley Investment Management Inc.||Company||5,255||NZ$31.63|
|17 May 22||BuyNZ$278,200,928||Hyperion Asset Management Limited||Company||10,860,282||NZ$25.62|
|13 May 22||BuyNZ$1,184,575||Mitsubishi UFJ Kokusai Asset Management Co., Ltd.||Company||41,272||NZ$28.70|
|12 May 22||BuyNZ$252,199,278||Pinnacle Investment Management Group Limited||Company||10,825,765||NZ$23.30|
|12 May 22||SellNZ$592,800||Mitsubishi UFJ Kokusai Asset Management Co., Ltd.||Company||19,578||NZ$30.28|
|11 May 22||SellNZ$12,616,456||Pinnacle Investment Management Group Limited||Company||492,781||NZ$25.60|
|11 May 22||SellNZ$15,498,497||Hyperion Asset Management Limited||Company||541,049||NZ$28.65|
|09 May 22||SellNZ$3,294,016||Mitsubishi UFJ Trust and Banking Corporation, Asset Management Arm||Company||106,356||NZ$30.97|
|29 Apr 22||BuyNZ$217,003||Morgan Stanley Investment Management Inc.||Company||6,926||NZ$31.33|
|06 Dec 21||BuyNZ$142,790||Lisa E. McIntyre||Individual||4,400||NZ$32.45|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Fisher & Paykel Healthcare Corporation Limited's employee growth, exchange listings and data sources
- Name: Fisher & Paykel Healthcare Corporation Limited
- Ticker: FPH
- Exchange: NZSE
- Founded: 1934
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: NZ$11.031b
- Shares outstanding: 577.53m
- Website: https://www.fphcare.com
Number of Employees
- Fisher & Paykel Healthcare Corporation Limited
- 15 Maurice Paykel Place
- East Tamaki
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FSPK.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jan 1992|
|FPH||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Jan 1992|
|FPH||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jan 1992|
|FPH||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jan 1992|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/26 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.